Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
24 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-08-09
Study Completion Date
2024-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Respiratory viral infections cause significant illness, especially in vulnerable individuals and is a topic of immense significance during the current COVID-19 global pandemic. Respiratory diseases such as asthma involve inflammation of the airways and viruses are a major cause of asthma attacks. The nose is easier to access than the lungs but has similar cells and is therefore useful to study immune responses throughout the respiratory tract.
Rather than study the effects of a live virus on the immune system, it is possible to give a component or mimic of a virus to simulate an infection in a similar but more straightforward manner, without causing disease.
In this study we will use a nasal spray containing a sterile substance called Resiquimod (also called R848) to mimic a viral infection. Resiquimod does not contain any living organisms and therefore there is no possibility of developing a real infection.
Resiquimod works by binding to receptors in cells that line the inside of the nose (epithelial cells) as well as cells that can fight infection (immune cells). These cells respond to Resiquimod and cause mild inflammation in the nose, similar to a mild cold. We can then take samples to measure this response and investigate how it differs between individuals. This will help us better understand how the human immune system responds to viruses, and which cells and molecules the body uses to defend itself against infection.
Rather than study the effects of a live virus on the immune system, it is possible to give a component or mimic of a virus to simulate an infection in a similar but more straightforward manner, without causing disease.
In this study we will use a nasal spray containing a sterile substance called Resiquimod (also called R848) to mimic a viral infection. Resiquimod does not contain any living organisms and therefore there is no possibility of developing a real infection.
Resiquimod works by binding to receptors in cells that line the inside of the nose (epithelial cells) as well as cells that can fight infection (immune cells). These cells respond to Resiquimod and cause mild inflammation in the nose, similar to a mild cold. We can then take samples to measure this response and investigate how it differs between individuals. This will help us better understand how the human immune system responds to viruses, and which cells and molecules the body uses to defend itself against infection.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19
NCT05069610
COVID-19
COMPLETED
PHASE1/PHASE2
Nebulized Nasal Steroids
NCT07270302
Chronic Rhinosinusitis
NOT_YET_RECRUITING
PHASE1/PHASE2
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
NCT06120244
Healthy
RECRUITING
Nitric Oxide Releasing Sinus Irrigation (NOSi) to Treat Recalcitrant Chronic Rhinosinusitis (RCRS)
NCT04163978
Chronic Sinusitis
COMPLETED
PHASE2
Blown Nasal Secretion Measurements in Rhinosinusitis: Repeatability and Validity Compared to Nasal Lavage
NCT00292851
Rhinosinusitis
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background Acute respiratory viral infections cause significant morbidity, especially in vulnerable individuals and is a topic of immense significance during the current COVID-19 global pandemic. Respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) involve inflammation of the airways and viruses are a major cause of exacerbations. Whilst new biological drugs targeting allergic and eosinophilic immune pathways have been developed for allergic asthma, therapeutic options for treating asthma exacerbations remain limited and rely on decades-old blunt tools such as oral corticosteroids. Development of new therapies and vaccines to combat viral respiratory tract infections is slow, partly because of the limited understanding of innate immune responses at the respiratory mucosal site of disease. Detailed characterization of such responses can facilitate biomarker definition for respiratory diseases, providing mechanistic insights and a platform for the testing of novel therapeutics.
Our understanding of the role of innate immunity to infection has recently undergone a paradigm shift as it is now recognized that innate cells (and not just adaptive immune cells) have the capacity to undergo "training" after infection via metabolic changes and epigenetic reprogramming. Pathogens can therefore modulate chromatin structure and the transcriptional programme of innate immune cells, which can result in altered but non-specific responses upon reinfection either with the same or heterologous stimuli. These epigenetic mechanisms may be particularly relevant in understanding how viral triggers (e.g. influenza) can lead to increased susceptibility to bacterial infections and cause pneumonia (e.g. due to streptococcus spp.).
Most studies have focused on peripheral immune cells such as macrophages, but the concept of innate immune training has been extended to long-lived non-immune skin epithelial stem cells, which have the capacity for "inflammatory memory". Allergic inflammatory memory has also recently been established in respiratory progenitor cells. Murine studies have highlighted the potential for structural cells (such as epithelial cells) to have the potential to mount immune responses. However, mechanisms of innate immune "memory" in human respiratory mucosal epithelial and immune cells in response to microbes and pathogen associated molecular patterns (PAMPs) are not well understood despite the respiratory tract being under a constant barrage of infectious stimuli.
Toll-like receptors (TLRs) play a critical role in the initial detection of microbes and PAMPs. TLR7/8 specifically detects RNA viruses such as influenza, rhinovirus, and coronavirus. Airway epithelial and immune cells express TLR7/8 and are therefore vital in mounting the innate immune response to viral infections, as well as helping shape adaptive immunity. Resiquimod (R848) is a single-stranded RNA viral analogue that binds to TLR7/8. When given systemically to treat human hepatitis C infection, it causes cytokine release and a flu-like syndrome. However, R848 has been successfully employed topically as a skin cream for actinic keratosis. TLR7 agonists have been developed for therapeutic use by repeated dose intranasal administration to target allergic inflammation in healthy volunteers and those with allergic rhinitis.
Rationale for current study Intranasal R848 administration has now been established in a human challenge model in healthy volunteers and in those with allergic rhinitis (AR) and allergic rhinitis with asthma (ARwA) by the chief investigator. In total, 44 volunteers have received intranasal R848 at a range of doses; 9 healthy volunteers received 10µg per nostril (n=9) with one person receiving 100µg per nostril (n=1); subsequently 35 volunteers received between 1-2µg per nostril based on weight (0.02µg/kg, healthy n=12, AR n=12, ARwA n=11). This dose was well tolerated by all volunteers with minimal nasal symptoms and no significant change in airflow obstruction (FEV1) in volunteers with asthma. Intranasal R848 was well tolerated systemically with no change in physiological measures or serum inflammatory mediators compared to saline challenge. The study demonstrated that individuals with AR and ARwA have increased nasal mucosal interferon and chemokine responses compared to healthy volunteers. This is coupled with the observation that there is a small and transient reduction in peripheral eosinophil counts at 4 hours and in lymphocyte counts at 24 hours, a finding limited to volunteers with AR and ARwA. This suggests that leukocyte trafficking may be occurring from the peripheral blood to the nasal mucosa. These findings highlight that dysregulated mucosal innate immune responses are likely to be important in determining the clinical outcome of viral triggers.
R848 nasal challenge (up to 2µg per nostril) is therefore a practical, tolerable, and non-invasive method to stimulate and investigate TLR-driven respiratory mucosal innate immune responses in both health and disease.
Defining the cellular basis for TLR-driven innate immunity will help provide mechanistic insights into how these responses differ between individuals, its dysregulation in disease (such as during an asthma exacerbation) and susceptibility to secondary infections. Understanding the epigenetic mechanisms which regulate interferon and chemokine production may help identify the molecular drivers of excessive or dampened inflammation, helping to refine potential therapeutic targets. Given the current COVID-19 pandemic, the clinical translational model utilised in this study allows for a practical and straightforward method to assess the host factors which determine respiratory mucosal innate immunity.
The goal of this project is to utilize an established tolerable human nasal TLR agonist challenge model combined with single-cell transcriptomic and epigenetic techniques to precisely characterize innate immune responses and mechanisms of innate immune training in airway epithelial and immune cells. Samples will be collected from the nasal mucosa and blood before and after saline and R848 challenge. Cell cultures from airway epithelium and blood will also be established to assess the functional impact of R848 on cellular response to repeat stimulation with viral and bacterial ligands. Study populations will include healthy participants and those with allergic rhinitis with/without asthma in order to investigate how in-vivo innate immunity is altered in these populations. Some participants will also undergo repeat nasal challenge to assess mechanisms of innate immune memory in the respiratory tract.
Our understanding of the role of innate immunity to infection has recently undergone a paradigm shift as it is now recognized that innate cells (and not just adaptive immune cells) have the capacity to undergo "training" after infection via metabolic changes and epigenetic reprogramming. Pathogens can therefore modulate chromatin structure and the transcriptional programme of innate immune cells, which can result in altered but non-specific responses upon reinfection either with the same or heterologous stimuli. These epigenetic mechanisms may be particularly relevant in understanding how viral triggers (e.g. influenza) can lead to increased susceptibility to bacterial infections and cause pneumonia (e.g. due to streptococcus spp.).
Most studies have focused on peripheral immune cells such as macrophages, but the concept of innate immune training has been extended to long-lived non-immune skin epithelial stem cells, which have the capacity for "inflammatory memory". Allergic inflammatory memory has also recently been established in respiratory progenitor cells. Murine studies have highlighted the potential for structural cells (such as epithelial cells) to have the potential to mount immune responses. However, mechanisms of innate immune "memory" in human respiratory mucosal epithelial and immune cells in response to microbes and pathogen associated molecular patterns (PAMPs) are not well understood despite the respiratory tract being under a constant barrage of infectious stimuli.
Toll-like receptors (TLRs) play a critical role in the initial detection of microbes and PAMPs. TLR7/8 specifically detects RNA viruses such as influenza, rhinovirus, and coronavirus. Airway epithelial and immune cells express TLR7/8 and are therefore vital in mounting the innate immune response to viral infections, as well as helping shape adaptive immunity. Resiquimod (R848) is a single-stranded RNA viral analogue that binds to TLR7/8. When given systemically to treat human hepatitis C infection, it causes cytokine release and a flu-like syndrome. However, R848 has been successfully employed topically as a skin cream for actinic keratosis. TLR7 agonists have been developed for therapeutic use by repeated dose intranasal administration to target allergic inflammation in healthy volunteers and those with allergic rhinitis.
Rationale for current study Intranasal R848 administration has now been established in a human challenge model in healthy volunteers and in those with allergic rhinitis (AR) and allergic rhinitis with asthma (ARwA) by the chief investigator. In total, 44 volunteers have received intranasal R848 at a range of doses; 9 healthy volunteers received 10µg per nostril (n=9) with one person receiving 100µg per nostril (n=1); subsequently 35 volunteers received between 1-2µg per nostril based on weight (0.02µg/kg, healthy n=12, AR n=12, ARwA n=11). This dose was well tolerated by all volunteers with minimal nasal symptoms and no significant change in airflow obstruction (FEV1) in volunteers with asthma. Intranasal R848 was well tolerated systemically with no change in physiological measures or serum inflammatory mediators compared to saline challenge. The study demonstrated that individuals with AR and ARwA have increased nasal mucosal interferon and chemokine responses compared to healthy volunteers. This is coupled with the observation that there is a small and transient reduction in peripheral eosinophil counts at 4 hours and in lymphocyte counts at 24 hours, a finding limited to volunteers with AR and ARwA. This suggests that leukocyte trafficking may be occurring from the peripheral blood to the nasal mucosa. These findings highlight that dysregulated mucosal innate immune responses are likely to be important in determining the clinical outcome of viral triggers.
R848 nasal challenge (up to 2µg per nostril) is therefore a practical, tolerable, and non-invasive method to stimulate and investigate TLR-driven respiratory mucosal innate immune responses in both health and disease.
Defining the cellular basis for TLR-driven innate immunity will help provide mechanistic insights into how these responses differ between individuals, its dysregulation in disease (such as during an asthma exacerbation) and susceptibility to secondary infections. Understanding the epigenetic mechanisms which regulate interferon and chemokine production may help identify the molecular drivers of excessive or dampened inflammation, helping to refine potential therapeutic targets. Given the current COVID-19 pandemic, the clinical translational model utilised in this study allows for a practical and straightforward method to assess the host factors which determine respiratory mucosal innate immunity.
The goal of this project is to utilize an established tolerable human nasal TLR agonist challenge model combined with single-cell transcriptomic and epigenetic techniques to precisely characterize innate immune responses and mechanisms of innate immune training in airway epithelial and immune cells. Samples will be collected from the nasal mucosa and blood before and after saline and R848 challenge. Cell cultures from airway epithelium and blood will also be established to assess the functional impact of R848 on cellular response to repeat stimulation with viral and bacterial ligands. Study populations will include healthy participants and those with allergic rhinitis with/without asthma in order to investigate how in-vivo innate immunity is altered in these populations. Some participants will also undergo repeat nasal challenge to assess mechanisms of innate immune memory in the respiratory tract.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Innate Inflammatory Response
Asthma
Nasal Allergy
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single nasal challenge R848 allergic rhinitis
Group Type
OTHER
R848
Intervention Type
DRUG
Nasal R848 administration
Single nasal challenge R848 healthy
Group Type
OTHER
R848
Intervention Type
DRUG
Nasal R848 administration
Single nasal challenge saline
Single nasal challenge saline allergic rhinitis and healthy
Group Type
OTHER
Saline
Intervention Type
DRUG
Nasal saline administration
Repeat nasal challenge R848 allergic rhinitis
Group Type
OTHER
R848
Intervention Type
DRUG
Nasal R848 administration
Repeat nasal challenge R848 healthy
Group Type
OTHER
R848
Intervention Type
DRUG
Nasal R848 administration
Repeat nasal challenge saline
Repeat nasal challenge saline allergic rhinitis and healthy
Group Type
OTHER
Saline
Intervention Type
DRUG
Nasal saline administration
Sample collection only
Sample collection only (no nasal challenge) to optimise laboratory protocols
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
R848
Nasal R848 administration
Intervention Type
DRUG
Saline
Nasal saline administration
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant is willing and able to give informed consent for participation in the study.
* Male or female aged 18 years and above
* Able (in the Investigators opinion) and willing to comply with all study requirements.
* Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.
* Female participants of child-bearing potential and male participants whose partner is of child-bearing potential must be willing to ensure that they or their partner use effective contraception during the study
* Participant has clinically acceptable laboratory and ECG at enrolment.
* Negative lateral flow or polymerase chain reaction (PCR) test for SARS-CoV-2
* For healthy volunteers:
* No clinical history of allergic rhinitis, asthma or eczema
* Negative skin prick tests or specific IgE response to a panel of common aeroallergens: cat, dog, grass pollen, tree pollen, house dust mite, fungal spores
* Normal blood eosinophil count (\< 300 cells/μL)
* Normal baseline forced expiratory volume (FEV1) i.e. ≥80%
* For volunteers with allergic rhinitis with or without asthma:
* A clinical history of allergic rhinitis symptoms (sneezing, runny or itchy nose) in response to aeroallergens
* At least one positive skin-prick test or specific IgE response to a panel of common aeroallergens: cat, dog, grass pollen, tree pollen, house dust mite, fungal spores
* Pre-bronchodilator FEV1 ≥50% predicted
* Participants are permitted to have physician-diagnosed mild to moderate asthma which is not poorly controlled as evidenced by an Asthma Control Questionnaire (ACQ-5) score of ≤1.5.
* If they have asthma, they are permitted to be on inhaled corticosteroid (ICS) and a long-acting beta agonist (LABA), but no other controller medication.
* Have had no other courses of medication including nasal and systemic corticosteroids, whether prescribed or over-the-counter, in the four weeks before first study dose other than mild analgesia, vitamins and mineral supplements or, for females, oral contraceptives.
* Male or female aged 18 years and above
* Able (in the Investigators opinion) and willing to comply with all study requirements.
* Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.
* Female participants of child-bearing potential and male participants whose partner is of child-bearing potential must be willing to ensure that they or their partner use effective contraception during the study
* Participant has clinically acceptable laboratory and ECG at enrolment.
* Negative lateral flow or polymerase chain reaction (PCR) test for SARS-CoV-2
* For healthy volunteers:
* No clinical history of allergic rhinitis, asthma or eczema
* Negative skin prick tests or specific IgE response to a panel of common aeroallergens: cat, dog, grass pollen, tree pollen, house dust mite, fungal spores
* Normal blood eosinophil count (\< 300 cells/μL)
* Normal baseline forced expiratory volume (FEV1) i.e. ≥80%
* For volunteers with allergic rhinitis with or without asthma:
* A clinical history of allergic rhinitis symptoms (sneezing, runny or itchy nose) in response to aeroallergens
* At least one positive skin-prick test or specific IgE response to a panel of common aeroallergens: cat, dog, grass pollen, tree pollen, house dust mite, fungal spores
* Pre-bronchodilator FEV1 ≥50% predicted
* Participants are permitted to have physician-diagnosed mild to moderate asthma which is not poorly controlled as evidenced by an Asthma Control Questionnaire (ACQ-5) score of ≤1.5.
* If they have asthma, they are permitted to be on inhaled corticosteroid (ICS) and a long-acting beta agonist (LABA), but no other controller medication.
* Have had no other courses of medication including nasal and systemic corticosteroids, whether prescribed or over-the-counter, in the four weeks before first study dose other than mild analgesia, vitamins and mineral supplements or, for females, oral contraceptives.
Exclusion Criteria
* Recent infections in past 14 days before screening: especially upper respiratory tract illnesses (including colds and influenza), sore throats, sinusitis, infective conjunctivitis.
* Lower respiratory tract infection in past 28 days
* Nasal anatomical defects, precluding use of nasal sampling techniques
* The participant may not enter the study if any of the following apply:
* Female participants who are pregnant, lactating or planning pregnancy during the study.
* Respiratory diseases (other than hay fever or asthma where specified)
* Significant medical history of hepatic, cardiovascular, gastrointestinal, renal, endocrine, infective, haematological, autoimmune, metabolic, rheumatological, neurological, dermatological or neoplastic conditions
* Extreme obesity (BMI \>40)
* Depression and psychiatric disorders
* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
* Participants who have participated in another research study involving an investigational product in the past 12 weeks
* Smoking in previous 6 months
* Lower respiratory tract infection in past 28 days
* Nasal anatomical defects, precluding use of nasal sampling techniques
* The participant may not enter the study if any of the following apply:
* Female participants who are pregnant, lactating or planning pregnancy during the study.
* Respiratory diseases (other than hay fever or asthma where specified)
* Significant medical history of hepatic, cardiovascular, gastrointestinal, renal, endocrine, infective, haematological, autoimmune, metabolic, rheumatological, neurological, dermatological or neoplastic conditions
* Extreme obesity (BMI \>40)
* Depression and psychiatric disorders
* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
* Participants who have participated in another research study involving an investigational product in the past 12 weeks
* Smoking in previous 6 months
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cambridge University Hospitals NHS Foundation Trust
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Akhilesh Jha
Clinical Lecturer in Respiratory Medicine
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cambridge University Hospitals NHS Foundation Trust
Cambridge, Cambridgeshire, United Kingdom
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United Kingdom
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Akhilesh Jha
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Jha A, Thwaites RS, Tunstall T, Kon OM, Shattock RJ, Hansel TT, Openshaw PJM. Increased nasal mucosal interferon and CCL13 response to a TLR7/8 agonist in asthma and allergic rhinitis. J Allergy Clin Immunol. 2021 Feb;147(2):694-703.e12. doi: 10.1016/j.jaci.2020.07.012. Epub 2020 Jul 24.
Reference Type
BACKGROUND
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A095696
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People
NCT06048393
UNKNOWN
PHASE1
Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19
NCT05541510
TERMINATED
PHASE2/PHASE3
Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen
NCT02090374
COMPLETED
NA
Sinusitis in Children and the Nasopharyngeal Microbiome
NCT01492868
COMPLETED
A Study of an Experimental Nasal Spray in Subjects With Early Signs of the Common Cold
NCT01488604
COMPLETED
NA
Characterisation of the Nasal Microbiome in Patients With N-ERD
NCT04375293
COMPLETED
NA
Efficacy and Safety Study of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults
NCT00344942
TERMINATED
PHASE3
Local Nasal Tolerability and Safety Study of 1146A in Healthy Adult Participants
NCT02832362
COMPLETED
PHASE1
Impact of Budesonide Irrigations on Patients With Chronic Rhinosinusitis and Impact on Sinus Surgery Rates
NCT03519061
WITHDRAWN
PHASE2/PHASE3
Nasal Lavage Study: Comparing Single Versus Multi Sample Lavages
NCT00229190
COMPLETED
NA
A Nasal Treatment for COVID-19
NCT05799521
RECRUITING
PHASE2
SB705498 Proof of Concept Chamber Challenge in Subjects With Non Allergic Rhinitis
NCT01424514
COMPLETED
PHASE2
Effects of Allergic Rhinitis on the Nasal/Sinus Microbiome
NCT01461200
COMPLETED
A Study to Determine the Tolerability of Intranasal LMN-301
NCT06030414
COMPLETED
PHASE1
Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection
NCT05109611
TERMINATED
PHASE3
NasoNeb Delivery of an Intranasal Steroid
NCT01270256
COMPLETED
PHASE4
Study to Evaluate Safety and Activity of TRL1068 in Chronic Rhinosinusitis
NCT05355207
UNKNOWN
PHASE1
Cleanoze® Irrigation Device With Powder Preparation Versus Conventional Irrigation Method for Chronic Rhinitis
NCT02763241
COMPLETED
PHASE3
Study of Asthma and Nasal Steroids
NCT01118312
COMPLETED
PHASE4
COVID-19 and Acute Invasive Fungal Rhinosinusitis
NCT04809480
COMPLETED
A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray
NCT07259538
RECRUITING
PHASE1
An Observational Study to Evaluate The Relationship of Nasal Mucus Properties and Symptoms
NCT01553110
COMPLETED
Nasal LPS Challenge in Healthy Volunteers
NCT02284074
COMPLETED
NA
Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Sinusitis
NCT06076304
RECRUITING
PHASE4